VSY Biotechnology Signs Agreement with Wakamoto Pharmaceutical on Intraocular Lens Products

VSY Biotechnology announced an agreement with Wakamoto Pharmaceutical to provide new treatments for cataract surgeries in Japan. The agreement includes a licensing arrangement with Wakamoto Pharmaceutical to develop and launch IOLs in Japan.

“We’re very excited to work with Wakamoto Pharmaceutical with our IOLs we have developed to inspire surgeons to have smooth and successful surgeries and people who have cataract to see and live better,” Fatih Ergin, CEO, VSY Biotechnology, said in a company news release.

“This in-licensing of IOLs will be an entry into a new field called ‘medical device’ for us, and we hope that we can make further contributions to patients in need of treatment by means other than pharmaceuticals.” said Norihisa Kojima, President & COO Wakamoto Pharmaceutical.

VSY Biotechnology also announced the appointment of seasoned executive leader Can Ongen to the company’s Board of Directors. In this role, Mr. Ongen will also lead VSY Biotechnology’s sales and marketing activities.

Mr. Ongen brings over 25 years of global leadership experience in medical devices, surgical implants, capital equipment, consumer and pharmaceuticals, having served in senior executive global commercial and marketing roles for Alcon and Galderma.

“We are delighted to welcome Can to our Board of Directors.” said Mr. Ercan Varlibas, Chairman of the Board of VSY Biotechnology. “Can is ideally suited to help us achieve our ambitious growth strategy. His extensive experience in successfully accomplishing sustainable growth and business expansion will be a tremendous asset as we seek to strengthen the global business of VSY Biotechnology.”